A single-arm, phase II study of autophagy modulation using hydroxychloroquine in addition to encorafenib and cetuximab or panitumumab in metastatic BRAF-mutated colorectal cancer refractory to standard therapy.

被引：0
|
作者：
Vakkalagadda, Chetan
Mukit, Sabeeha
Kocherginsky, Masha
Kircher, Sheetal Mehta
Kalyan, Aparna
Mulcahy, Mary Frances
Benson, Al Bowen
Chandel, Navdeep
Mahalingam, Devalingam
机构：
[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS262
引用
收藏
页码：TPS262 / TPS262
页数：1
相关论文
共 50 条
  • [1] A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
    Chen, Xiaofeng
    Qiu, Tianzhu
    Zhu, Yingwei
    Sun, Jing
    Li, Ping
    Wang, Biao
    Lin, Peinan
    Cai, Xiaomin
    Han, Xiao
    Zhao, Fengjiao
    Shu, Yongqian
    Chang, Lianpeng
    Jiang, Hua
    Gu, Yanhong
    ONCOLOGIST, 2019, 24 (07): : 883 - +
  • [2] Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
    Kopetz, Scott
    Desai, Jayesh
    Chan, Emily
    Hecht, Joel Randolph
    O'Dwyer, Peter J.
    Maru, Dipen
    Van Morris
    Janku, Filip
    Dasari, Arvind
    Chung, Woonbook
    Issa, Jean-Pierre J.
    Gibbs, Peter
    James, Brian
    Powis, Garth
    Nolop, Keith B.
    Bhattacharya, Suman
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4032 - 4038
  • [3] PACER - A multicentre, single-arm, two-stage, phase 2 study of panitumumab in patients with cetuximab-refractory metastatic colorectal cancer (mCRC)
    Daniele, B.
    Iaffaioli, R. V.
    Chiara, C.
    Maiello, E.
    Rosati, G.
    Alabiso, O.
    Nasti, G.
    De Stefano, A.
    Latiano, T. P.
    Bilancia, D.
    Barletta, E.
    Ottaiano, A.
    Romano, C.
    Silvestro, L.
    Avallone, A.
    Lambiase, M.
    Normanno, N.
    Daniele, G.
    Perrone, F.
    Piccirillo, M. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial
    Piccirillo, Maria Carmela
    Avallone, Antonio
    Carlomagno, Chiara
    Maiello, Evaristo
    Rosati, Gerardo
    Alabiso, Oscar
    Nasti, Guglielmo
    De Placido, Sabino
    Latiano, Tizana Pia
    Bilancia, Domenico
    Ottaiano, Alessandro
    De Stefano, Alfonso
    Romano, Carmela
    Silvestro, Lucrezia
    Nappi, Anna
    Cassata, Antonino
    Giordano, Pasqualina
    Iaffaioli, Rosario Vincenzo
    Normanno, Nicola
    Perrone, Francesco
    Daniele, Bruno
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : 270 - 276
  • [5] ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer
    Grothey, A.
    Tabernero, J.
    Taieb, J.
    Yaeger, R.
    Yoshino, T.
    Maiello, E.
    Fernandez, E. Elez
    Casado, A. Ruiz
    Ross, P.
    Andre, T.
    Kato, T.
    Ruffinelli, J.
    Graham, J.
    Van den Eynde, M.
    Vera, R.
    Jean, B.
    Roussel, E. Carriere
    Cahuzac, C.
    Issiakhem, Z.
    Vedovato, J.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S242 - S243
  • [6] An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
    Van Cutsem, E.
    Siena, S.
    Humblet, Y.
    Canon, J. -L.
    Maurel, J.
    Bajetta, E.
    Neyns, B.
    Kotasek, D.
    Santoro, A.
    Scheithauer, W.
    Spadafora, S.
    Amado, R. G.
    Hogan, N.
    Peeters, M.
    ANNALS OF ONCOLOGY, 2008, 19 (01) : 92 - 98
  • [7] Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.
    Hong, David S.
    Morris, Van Karlyle
    El Osta, Badi Edmond
    Fu, Siqing
    Overman, Michael J.
    Piha-Paul, Sarina Anne
    Subbiah, Vivek
    Kee, Bryan K.
    Tsimberidou, Apostolia Maria
    Zinner, Ralph
    Fogelman, David R.
    Bellido, Jorge
    Shureiqi, Imad
    Meric-Bernstam, Funda
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Safety and efficacy of encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: A systematic review and single-arm meta-analysis
    Celso, D. S. G.
    Defante, M. L. R.
    Alzogaray, V.
    Torres, L. A.
    Lopes, A. C. Melo
    Bearse, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S29 - S29
  • [9] A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
    Martina Eriksen
    Per Pfeiffer
    Kristoffer Staal Rohrberg
    Christina Westmose Yde
    Lone Nørgård Petersen
    Laurids Østergaard Poulsen
    Camilla Qvortrup
    BMC Cancer, 22
  • [10] A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
    Eriksen, Martina
    Pfeiffer, Per
    Rohrberg, Kristoffer Staal
    Yde, Christina Westmose
    Petersen, Lone Norgard
    Poulsen, Laurids Ostergaard
    Qvortrup, Camilla
    BMC CANCER, 2022, 22 (01)
12345